Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,189 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effectiveness of dolutegravir-based regimens as either first-line or switch antiretroviral therapy: data from the Icona cohort.
Mondi A, Cozzi-Lepri A, Tavelli A, Rusconi S, Vichi F, Ceccherini-Silberstein F, Calcagno A, De Luca A, Maggiolo F, Marchetti G, Antinori A, d'Arminio Monforte A; Icona Foundation Study Group. Mondi A, et al. Among authors: de luca a. J Int AIDS Soc. 2019 Jan;22(1):e25227. doi: 10.1002/jia2.25227. J Int AIDS Soc. 2019. PMID: 30663278 Free PMC article.
Timing of antiretroviral therapy initiation after a first AIDS-defining event: temporal changes in clinical attitudes in the ICONA cohort.
Cingolani A, Cozzi-Lepri A, Ammassari A, Mussini C, Ursitti MA, Caramello P, Angarano G, Bonfanti P, De Luca A, Mura MS, Girardi E, Antinori A, Monforte AD; Icona Foundation Study group. Cingolani A, et al. Among authors: de luca a. PLoS One. 2014 Feb 27;9(2):e89861. doi: 10.1371/journal.pone.0089861. eCollection 2014. PLoS One. 2014. PMID: 24587081 Free PMC article.
Discontinuation of Initial Antiretroviral Therapy in Clinical Practice: Moving Toward Individualized Therapy.
Di Biagio A, Cozzi-Lepri A, Prinapori R, Angarano G, Gori A, Quirino T, De Luca A, Costantini A, Mussini C, Rizzardini G, Castagna A, Antinori A, dʼArminio Monforte A; ICONA Foundation Study Group. Di Biagio A, et al. Among authors: de luca a. J Acquir Immune Defic Syndr. 2016 Mar 1;71(3):263-71. doi: 10.1097/QAI.0000000000000849. J Acquir Immune Defic Syndr. 2016. PMID: 26871881 Free PMC article.
Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort.
d'Arminio Monforte A, Cozzi-Lepri A, Maggiolo F, Rizzardini G, Manconi PE, Gianotti N, Quirino T, Pinnetti C, Rusconi S, De Luca A, Antinori A; Icona Foundation Study cohort. d'Arminio Monforte A, et al. Among authors: de luca a. PLoS One. 2016 Jun 27;11(6):e0156360. doi: 10.1371/journal.pone.0156360. eCollection 2016. PLoS One. 2016. PMID: 27348592 Free PMC article.
Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort.
d'Arminio Monforte A, Cozzi-Lepri A, Ceccherini-Silberstein F, De Luca A, Lo Caputo S, Castagna A, Mussini C, Cingolani A, Tavelli A, Shanyinde M, Gori A, Girardi E, Andreoni M, Antinori A, Puoti M; Icona Foundation and HepaIcona Study Group. d'Arminio Monforte A, et al. Among authors: de luca a. PLoS One. 2017 May 17;12(5):e0177402. doi: 10.1371/journal.pone.0177402. eCollection 2017. PLoS One. 2017. PMID: 28520749 Free PMC article.
Durability of Second Antiretroviral Regimens in the Italian Cohort Naive Antiretrovirals Foundation Study and Factors Associated with Discontinuation.
Di Biagio A, Lorenzini P, Gustinetti G, Rusconi S, De Luca A, Lapadula G, Lo Caputo S, Cicalini S, Castelli F, Marchetti G, Antinori A, Monforte AD. Di Biagio A, et al. Among authors: de luca a. AIDS Patient Care STDS. 2017 Dec;31(12):487-494. doi: 10.1089/apc.2017.0140. AIDS Patient Care STDS. 2017. PMID: 29211512 Free article.
Incidence and predictors of single drug discontinuation according to the presence of HCV coinfection in HIV patients from the ICONA Foundation Cohort Study.
Leone S, Shanyinde M, Cozzi Lepri A, Lampe FC, Caramello P, Costantini A, Giacometti A, De Luca A, Cingolani A, Ceccherini Silberstein F, Puoti M, Gori A, d'Arminio Monforte A; ICONA Foundation Cohort Study. Leone S, et al. Among authors: de luca a. Eur J Clin Microbiol Infect Dis. 2018 May;37(5):871-881. doi: 10.1007/s10096-017-3180-8. Epub 2018 Jan 9. Eur J Clin Microbiol Infect Dis. 2018. PMID: 29318459 Free article.
Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART.
Ceccherini-Silberstein F, Cozzi Lepri A, Alteri C, Merlini E, Surdo M, Marchetti G, Capobianchi MR, De Luca A, Gianotti N, Viale P, Andreoni M, Antinori A, Perno CF, d'Arminio Monforte A; ICONA Foundation Study Group. Ceccherini-Silberstein F, et al. Among authors: de luca a. J Antimicrob Chemother. 2018 Dec 1;73(12):3460-3470. doi: 10.1093/jac/dky350. J Antimicrob Chemother. 2018. PMID: 30247724 Free article.
Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL.
Gianotti N, Lorenzini P, Cozzi-Lepri A, De Luca A, Madeddu G, Sighinolfi L, Pinnetti C, Santoro C, Meraviglia P, Mussini C, Antinori A, d'Arminio Monforte A; ICONA Foundation Study Group. Gianotti N, et al. Among authors: de luca a. J Antimicrob Chemother. 2019 Sep 1;74(9):2732-2741. doi: 10.1093/jac/dkz237. J Antimicrob Chemother. 2019. PMID: 31173639
Durability of rilpivirine-based versus integrase inhibitor-based regimens in a large cohort of naïve HIV-infected patients starting antiretroviral therapy.
Gagliardini R, Gianotti N, Maggiolo F, Cozzi-Lepri A, Antinori A, Nozza S, Lapadula G, De Luca A, Mussini C, Gori A, Saracino A, Andreoni M, Monforte AD; ICONA Foundation Study Group. Gagliardini R, et al. Among authors: de luca a. Int J Antimicrob Agents. 2021 Oct;58(4):106406. doi: 10.1016/j.ijantimicag.2021.106406. Epub 2021 Jul 19. Int J Antimicrob Agents. 2021. PMID: 34293454
2,189 results